AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34545613 — intervention group
Group type: COMPARATOR
Intervention: 1/3 finger‐tip unit equivalent dose of Hirudoid Cream 0.3% applied twice daily for 28 days
Number of subjects: 60
Study 34545613 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 finger‐tip unit equivalent dose of Hirudoid Cream 0.3%
Number of subjects: 60
Study 34545613 — intervention group
Group type: COMPARATOR
Intervention: 1/3 finger‐tip unit equivalent dose of Hirudoid Cream 0.3%
Number of subjects: 60
Study 34296782 — intervention group
Group type: EXPERIMENTAL
Intervention: Unique unrelated question randomized response model
Number of subjects: 0
Study 32569087 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 318
Study 32569087 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment in first treatment period
Number of subjects: 318
Study 32569087 — intervention group
Group type: COMPARATOR
Intervention: Trial-specific factors (treatment sequence, chance of having placebo treatment)
Number of subjects: 318
Study 32569087 — intervention group
Group type: COMPARATOR
Intervention: Patient-specific factors (age, sensory signs, pain symptoms)
Number of subjects: 318
Study 35133516 — intervention group
Group type: EXPERIMENTAL
Intervention: HBOT (two absolute atmospheres (ATA), breathing 100% oxygen for 1 h)
Number of subjects: 37
Study 34863239 — intervention group
Group type: EXPERIMENTAL
Intervention: rESWT
Number of subjects: 140
Study 34863239 — intervention group
Group type: EXPERIMENTAL
Intervention: rESWT + C + E
Number of subjects: 140
Study 34863239 — intervention group
Group type: COMPARATOR
Intervention: C + E
Number of subjects: 140
Study 35640225 — intervention group
Group type: COMPARATOR
Intervention: Standard behavioral weight loss treatment (BT)
Number of subjects: 320
Study 35640225 — intervention group
Group type: EXPERIMENTAL
Intervention: BT with a focus on physical activity (PA)
Number of subjects: 320
Study 35640225 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance-based therapy (ABT) with a focus on PA
Number of subjects: 320
Study 35640225 — intervention group
Group type: EXPERIMENTAL
Intervention: High physical activity engagement
Number of subjects: 320
Study 35640225 — intervention group
Group type: EXPERIMENTAL
Intervention: Low emotional eating
Number of subjects: 320
Study 35640225 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief that exercise does not affect appetite
Number of subjects: 320
Study 33900585 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 0
Study 33900585 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 0
Study 33900585 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 0
Study 32629291 — intervention group
Group type: EXPERIMENTAL
Intervention: Online cognitive training focused on executive functioning
Number of subjects: 228
Study 32629291 — intervention group
Group type: COMPARATOR
Intervention: Online cognitive training focused on other cognitive abilities (Control)
Number of subjects: 228
Study 34599401 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy laser therapy (LLT) plus exercises
Number of subjects: 60
Study 34599401 — intervention group
Group type: COMPARATOR
Intervention: Exercises alone (control group)
Number of subjects: 60
Study 32951632 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP plus usual care
Number of subjects: 2687
Study 32951632 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 2687
Study 35759949 — intervention group
Group type: EXPERIMENTAL
Intervention: Multithematic health coaching
Number of subjects: 149
Study 35759949 — intervention group
Group type: COMPARATOR
Intervention: Smoking cessation counselling
Number of subjects: 149
Study 34641941 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) therapy after static stretching
Number of subjects: 22
Study 34641941 — intervention group
Group type: COMPARATOR
Intervention: Stretching only
Number of subjects: 22
Study 32433273 — intervention group
Group type: EXPERIMENTAL
Intervention: LFD/B-GOS (1.4 g/d)
Number of subjects: 69
Study 32433273 — intervention group
Group type: COMPARATOR
Intervention: Control (sham diet with placebo supplement)
Number of subjects: 69
Study 32433273 — intervention group
Group type: EXPERIMENTAL
Intervention: LFD
Number of subjects: 69
Study 32433273 — intervention group
Group type: EXPERIMENTAL
Intervention: LFD/B-GOS
Number of subjects: 69
Study 35899378 — intervention group
Group type: EXPERIMENTAL
Intervention: Rozibafusp alfa (n = 26, doses of 70, 140, 210, and 420 mg)
Number of subjects: 34
Study 35899378 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 8)
Number of subjects: 34
Study 35899378 — intervention group
Group type: EXPERIMENTAL
Intervention: Rozibafusp alfa (210 and 420 mg cohorts)
Number of subjects: 34
Study 35899378 — intervention group
Group type: EXPERIMENTAL
Intervention: Rozibafusp alfa (all cohorts)
Number of subjects: 34
Study 35899378 — intervention group
Group type: EXPERIMENTAL
Intervention: Rozibafusp alfa (n = 26)
Number of subjects: 34
Study 32654554 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose carbidopa (600 mg/day)
Number of subjects: 22
Study 32654554 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose carbidopa (300 mg/day)
Number of subjects: 22
Study 32654554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 33762233 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed communication strategy
Number of subjects: 15000
Study 33762233 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed communication strategy
Number of subjects: 15000
Study 33762233 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term context communication strategy
Number of subjects: 15000
Study 33762233 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term context communication strategy
Number of subjects: 15000
Study 33271745 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc‐carbonate‐hydroxyapatite nanoparticle (CHA)
Number of subjects: 25
Study 33271745 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium sodium phosphosilicate bioactive glass (CSPS)
Number of subjects: 25
Study 33271745 — intervention group
Group type: COMPARATOR
Intervention: Herbal based toothpaste (HB)
Number of subjects: 25
Study 34990262 — intervention group
Group type: COMPARATOR
Intervention: Low-dose ara-C (LDAC, n=91)
Number of subjects: 166
Study 34990262 — intervention group
Group type: COMPARATOR
Intervention: Standard Ara-C, daunorubicin and etoposide (ADE, n=465)
Number of subjects: 166
Study 34990262 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented high-dose ara-C (HDAC, n=75)
Number of subjects: 166
Study 34990262 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented ADE + gemtuzumab ozogamicin (GO, n=466)
Number of subjects: 166
Study 34990262 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented therapy (AML02-HDAC or AAML0531-ADE + GO)
Number of subjects: 166
Study 34959850 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially‐hydrolysed guar gum (PHGG)
Number of subjects: 10
Study 34959850 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum Arabic
Number of subjects: 10
Study 34959850 — intervention group
Group type: COMPARATOR
Intervention: Psyllium husk
Number of subjects: 10
Study 34959850 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 10
Study 32641097 — intervention group
Group type: EXPERIMENTAL
Intervention: Central collection of screening logs
Number of subjects: 1138
Study 32641097 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach rate
Number of subjects: 1138
Study 32641097 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance rate
Number of subjects: 1138
Study 32641097 — intervention group
Group type: EXPERIMENTAL
Intervention: Reason for declining trial participation
Number of subjects: 1138
Study 35111274 — intervention group
Group type: EXPERIMENTAL
Intervention: MPM (paracetamol, ibuprofen, and arm physiotherapy)
Number of subjects: 137
Study 35111274 — intervention group
Group type: COMPARATOR
Intervention: Pain medication 'as needed' (Control)
Number of subjects: 137
Study 34304728 — intervention group
Group type: EXPERIMENTAL
Intervention: Contradictory message condition
Number of subjects: 763
Study 34304728 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-contradictory message condition
Number of subjects: 763
Study 34304728 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 763
Study 32407137 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) herbal formula, consumed twice daily for 3 months
Number of subjects: 79
Study 35549845 — intervention group
Group type: EXPERIMENTAL
Intervention: T2LOW exacerbations
Number of subjects: 301
Study 35549845 — intervention group
Group type: EXPERIMENTAL
Intervention: T2HIGH exacerbations
Number of subjects: 301
Study 33771848 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized advice based on cancer risk prediction
Number of subjects: 5984
Study 33771848 — intervention group
Group type: COMPARATOR
Intervention: Standard advice without risk prediction
Number of subjects: 5984
Study 34951009 — intervention group
Group type: EXPERIMENTAL
Intervention: TP53 mutated patients
Number of subjects: 125
Study 34951009 — intervention group
Group type: COMPARATOR
Intervention: TP53 wild-type patients
Number of subjects: 125
Study 34951009 — intervention group
Group type: EXPERIMENTAL
Intervention: TP53 mutations
Number of subjects: 125
Study 33227506 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 0
Study 33227506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35183232 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi combined with Kinesio taping (TC+KT)
Number of subjects: 53
Study 35183232 — intervention group
Group type: COMPARATOR
Intervention: Placebo Kinesio taping (TC+KTp)
Number of subjects: 53
Study 35183232 — intervention group
Group type: COMPARATOR
Intervention: Kinesio taping (KT)
Number of subjects: 53
Study 32279145 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 16
Study 35843174 — intervention group
Group type: EXPERIMENTAL
Intervention: NAB-PTX (nanoparticle albumin bound paclitaxel) administered via PIPAC at doses escalated from 35 to 140 mg/m2, with three treatments at four-week intervals.
Number of subjects: 23
Study 35843174 — intervention group
Group type: EXPERIMENTAL
Intervention: NAB-PTX (nanoparticle albumin bound paclitaxel) administered via PIPAC.
Number of subjects: 23
Study 32924749 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention with parents
Number of subjects: 66
Study 32924749 — intervention group
Group type: COMPARATOR
Intervention: Urotherapy orientation and psychological counseling (control group)
Number of subjects: 66
Study 32600406 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating doses of a nicotine patch (up to 84 mg)
Number of subjects: 400
Study 32600406 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo patches
Number of subjects: 400
Study 32600406 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 mg nicotine patch
Number of subjects: 400
Study 36258654 — intervention group
Group type: EXPERIMENTAL
Intervention: LivingWith® app used weekly for 3 months
Number of subjects: 224
Study 36258654 — intervention group
Group type: COMPARATOR
Intervention: Control group (no app usage)
Number of subjects: 224
Study 33651007 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block (posttetanic count 1 to 2)
Number of subjects: 0
Study 33651007 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block
Number of subjects: 0
Study 32028926 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) delivered via a mobile app (Manaaki) with six intervention modules, personalized feedback, and various engagement features.
Number of subjects: 284
Study 32028926 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group receiving a simple app that counts down to access the full app.
Number of subjects: 284
Study 32028926 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) delivered via a mobile app (Manaaki).
Number of subjects: 284
Study 35180555 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined risk messages
Number of subjects: 1004
Study 35180555 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 risk condition
Number of subjects: 1004
Study 35180555 — intervention group
Group type: COMPARATOR
Intervention: Smoking risk condition
Number of subjects: 1004
Study 35180555 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1004
Study 32770685 — intervention group
Group type: COMPARATOR
Intervention: Ablative fractional carbon dioxide (FCO2) laser
Number of subjects: 60
Study 32770685 — intervention group
Group type: COMPARATOR
Intervention: Autologous platelet-rich plasma (PRP)
Number of subjects: 60
Study 32770685 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of FCO2 laser and PRP
Number of subjects: 60
Study 34684862 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-rice (IR) drink (15 mg iron/serving) consumed by anemic group (C) for 30 days
Number of subjects: 4
Study 34684862 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-rice (IR) drink (27 mg iron/serving) consumed by non-anemic group (D) for 30 days
Number of subjects: 4
Study 34684862 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-rice (IR) drink (15 mg iron/serving) consumed by non-anemic group (A) for 30 days
Number of subjects: 4
Study 34684862 — intervention group
Group type: COMPARATOR
Intervention: WR drink (2 mg iron/serving) consumed by non-anemic group (A) for 30 days
Number of subjects: 4
Study 32130679 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC of ibuprofen/acetaminophen 250/500 mg (two tablets of ibuprofen 125 mg/acetaminophen 250 mg)
Number of subjects: 102
Study 32130679 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC of ibuprofen/acetaminophen 250/500 mg with food
Number of subjects: 102
Study 32130679 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC of ibuprofen/acetaminophen 250/500 mg in adolescents
Number of subjects: 102
Study 32130679 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC of ibuprofen/acetaminophen 250/500 mg in adolescents aged 12-14 years
Number of subjects: 102
Study 32130679 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC of ibuprofen/acetaminophen 250/500 mg
Number of subjects: 102
Study 34628687 — intervention group
Group type: EXPERIMENTAL
Intervention: CAL/BDP PAD-cream
Number of subjects: 0
Study 34628687 — intervention group
Group type: COMPARATOR
Intervention: CAL/BDP TS (active control)
Number of subjects: 0
Study 34014758 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of caffeine
Number of subjects: 276
Study 34014758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 34014758 — intervention group
Group type: COMPARATOR
Intervention: Sleep deprivation
Number of subjects: 276
Study 34271782 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (MgSO4) as intravenous infusion
Number of subjects: 0
Study 34271782 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard management without magnesium sulphate)
Number of subjects: 0
Study 32297646 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 10
Study 615919038 — intervention group
Group type: EXPERIMENTAL
Intervention: Right lateral decubitus position (RLD)
Number of subjects: 15
Study 615919038 — intervention group
Group type: COMPARATOR
Intervention: Left lateral decubitus position (LLD)
Number of subjects: 15
Study 34719101 — intervention group
Group type: EXPERIMENTAL
Intervention: 308-nm excimer light with bi-weekly intradermal PRP (group A)
Number of subjects: 36
Study 34719101 — intervention group
Group type: COMPARATOR
Intervention: 308-nm excimer light alone (group B)
Number of subjects: 36
Study 33229305 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led hospital-to-home bridging program with 4 weeks postdischarge follow-up (2 home visits and 2 telephone calls)
Number of subjects: 705
Study 33229305 — intervention group
Group type: COMPARATOR
Intervention: Control condition (standard care)
Number of subjects: 705
Study 33229305 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led hospital-to-home bridging program
Number of subjects: 705
Study 33823129 — intervention group
Group type: EXPERIMENTAL
Intervention: DS‐Cav1 vaccination
Number of subjects: 6
Study 32436964 — intervention group
Group type: EXPERIMENTAL
Intervention: Hem‐o‐lok clips
Number of subjects: 0
Study 32436964 — intervention group
Group type: COMPARATOR
Intervention: Intracorporeal knotting
Number of subjects: 0
Study 35409872 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-specific meal replacement (MR) replacing one meal for 5 days a week for 12 weeks
Number of subjects: 156
Study 35409872 — intervention group
Group type: COMPARATOR
Intervention: Routine dietary consultation
Number of subjects: 156
Study 35409872 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-specific meal replacement (MR)
Number of subjects: 156
Study 32264769 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents at risk for suicide
Number of subjects: 166
Study 32264769 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (matched by age and gender)
Number of subjects: 166
Study 32350903 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy
Number of subjects: 58
Study 32350903 — intervention group
Group type: COMPARATOR
Intervention: Oral hygiene instructions (Control)
Number of subjects: 58
Study 34961645 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer‐assisted navigation systems (CANS)
Number of subjects: 38
Study 34961645 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical treatment without CANS
Number of subjects: 38
Study 34225302 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT+LE
Number of subjects: 79
Study 34225302 — intervention group
Group type: COMPARATOR
Intervention: TME
Number of subjects: 79
Study 34225302 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 79
Study 36206822 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo beverage consumption
Number of subjects: 22
Study 32838641 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 134
Study 32445247 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional injections (ILIs) of triamcinolone acetonide (TA) combined with extracorporeal shock wave therapy (ESWT)
Number of subjects: 40
Study 32445247 — intervention group
Group type: COMPARATOR
Intervention: Intralesional injections (ILIs) of triamcinolone acetonide (TA) alone
Number of subjects: 40
Study 34996693 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling exercise
Number of subjects: 10
Study 34996693 — intervention group
Group type: COMPARATOR
Intervention: Repetitive nerve stimulation (RNS)
Number of subjects: 10
Study 32272914 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium citrate (300 mg magnesium citrate daily)
Number of subjects: 318
Study 32272914 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule (daily)
Number of subjects: 318
Study 34151502 — intervention group
Group type: EXPERIMENTAL
Intervention: SciMoCa (secondary Monte Carlo dose calculation)
Number of subjects: 30
Study 34151502 — intervention group
Group type: EXPERIMENTAL
Intervention: MLC shift errors
Number of subjects: 30
Study 34151502 — intervention group
Group type: EXPERIMENTAL
Intervention: Plausibility check of TPS Monaco vs. BP measurement and SciMoCa vs. BP measurement
Number of subjects: 30
Study 34151502 — intervention group
Group type: EXPERIMENTAL
Intervention: SciMoCa
Number of subjects: 30
Study 32666905 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic treatment register used in the DeWorm3 Project for mass drug administration.
Number of subjects: 0
Study 35852595 — intervention group
Group type: EXPERIMENTAL
Intervention: AIUSP
Number of subjects: 400
Study 35852595 — intervention group
Group type: COMPARATOR
Intervention: TRUS-SB
Number of subjects: 400
Study 35852595 — intervention group
Group type: COMPARATOR
Intervention: mpMRI
Number of subjects: 400
Study 33683419 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin supplementation
Number of subjects: 90
Study 33683419 — intervention group
Group type: COMPARATOR
Intervention: Control (COS protocol only)
Number of subjects: 90
Study 32683755 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA group
Number of subjects: 40
Study 32683755 — intervention group
Group type: COMPARATOR
Intervention: FTCS group
Number of subjects: 40
Study 35042751 — intervention group
Group type: EXPERIMENTAL
Intervention: Efpeglenatide (4 mg or 6 mg once weekly, 6 mg or 8 mg once every 2 weeks)
Number of subjects: 0
Study 35042751 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35042751 — intervention group
Group type: EXPERIMENTAL
Intervention: Efpeglenatide
Number of subjects: 0
Study 32001530 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive vincristine dosing
Number of subjects: 275
Study 32001530 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplantation (HCT)
Number of subjects: 275
Study 32001530 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD <0.1% at the end of Induction-1
Number of subjects: 275
Study 32001530 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD ≥0.1% at the end of Induction-1
Number of subjects: 275
Study 32001530 — intervention group
Group type: EXPERIMENTAL
Intervention: Early iCNS relapse
Number of subjects: 275
Study 33940113 — intervention group
Group type: EXPERIMENTAL
Intervention: EvoCit (heparin-grafted dialyzer with citrate-enriched dialysate)
Number of subjects: 26
Study 33940113 — intervention group
Group type: COMPARATOR
Intervention: EvoHep (heparin-grafted dialyzer with systemic heparin)
Number of subjects: 26
Study 33940113 — intervention group
Group type: EXPERIMENTAL
Intervention: EvoCit
Number of subjects: 26
Study 33940113 — intervention group
Group type: COMPARATOR
Intervention: EvoHep
Number of subjects: 26
Study 32753452 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 600
Study 32753452 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 600
Study 36423489 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Resistance Training (HIRT)
Number of subjects: 38
Study 36423489 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 38